> Researchers are studying several severe liver problems--and one death--among patients talking a novel antibiotic. Report
> Genitope has outlined plans to raise $38.5 million from the sale of common stock. Most of the money is earmarked for R&D purposes. Report
> Tanox has pocketed a $12.8 million milestone payment after sales of the asthma drug Xolair passed $300 million. Report
> Amgen is creating more than 800 new jobs in Ireland as it invests in a new manufacturing plant in Cork. Report
> Biovitrum of Sweden and Syntonix Pharmaceuticals have entered into a co-development agreement for Syntonix' recombinant Factor IX product for Hemophilia B. Under the terms of the agreement, Syntonix receives an initial collaboration fee and Biovitrum makes an equity investment in Syntonix. Release
> Paul Royalty Fund announced that an affiliate of the fund ("Paul Royalty") has purchased a royalty interest in Rotarix from three researchers at Cincinnati Children's Hospital Medical Center. Release
> India's Hikma Pharmaceuticals announced that all three of its drug businesses experienced higher sales in 2005. Report
> Merck's pharmaceutical unit chief says that the company is looking for new acquisitions, but added that Altana is not one of the companies it is considering buying. Report
> After evaluating Phase II data, Nymox Pharmaceutical's data monitoring committee has given a positive recommendation to its experimental therapy for benign prostatic hyperplasia. Release
And Finally… The Washington Post examines the recent accounting troubles of Cel-Sci, which may have to restate its financial results for 2001-2003. Report